The goal of this study was to define the role of
p38alpha MAP kinase in
VEGF-induced vascular permeability increase. Activation of p38 is correlated with increased permeability in endothelial cells treated with
VEGF or high
glucose and in retinas of diabetic animal models. We have shown previously that p38 inhibitors preserve endothelial barrier function and block
VEGF-induced GSK/
beta-catenin signaling. Here, we present data demonstrating that adenoviral vector delivery of a dominant negative p38alpha mutant blocks this signaling pathway and preserves barrier function. This p38alpha mutant was altered on its
ATP-binding site, which eliminates its
kinase activity. Bovine
retinal endothelial (BRE) cells were transduced with recombinant adenovirus containing the p38alpha mutants or empty vector. Successful transduction was confirmed by expression of GFP and p38 increase. Blockade of p38 activity by p38alpha mutant was demonstrated by inhibition of
VEGF-induced phosphorylation of a p38 target,
MAP kinase activated protein kinase 2 (MK-2). The mutant also prevented
VEGF-induced GSK phosphorylation and
beta-catenin cytosolic accumulation and nuclear translocation as shown by cell fractionation and Western blotting. Quantitative real-time PCR demonstrated that this mutant inhibited
VEGF-induced uPAR gene expression. Importantly, this same mutant also strongly abrogated
VEGF-induced endothelial barrier breakdown as determined by measuring transcellular electrical resistance and tracer flux through endothelial cell monolayer. This study indicates a critical role of p38alpha in
VEGF-induced permeability and offers a new strategy for developing potent and specific
therapies for treatment of
retinal diseases associated with vascular barrier dysfunction.